Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Scott Kopetz(The University of Texas MD Anderson Cancer Center), Howard S. Höchster(Rutgers, The State University of New Jersey), Shannon McDonough, Philip A. Philip(Wayne State University), Christopher H. Lieu(University of Colorado Denver), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), David S. Hong(The University of Texas MD Anderson Cancer Center), Stephen E Wang(Kaiser Permanente South Sacramento Medical Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Katherine A. Guthrie, Luis A. Díaz(Memorial Sloan Kettering Cancer Center), Alexey V. Sorokin(The University of Texas MD Anderson Cancer Center), Dipen M. Maru(The University of Texas MD Anderson Cancer Center), Chloé E. Atreya(The University of Texas MD Anderson Cancer Center), Carmen J. Allegra(National Cancer Institute), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Anthony M. Magliocco(Cancer Prevention Institute of California), Yibing Yan(Anhui Medical University), Van K. Morris(The University of Texas MD Anderson Cancer Center)
Cited by 391
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k